- Details
- Description
Strength:
Glecaprevir 100 mg + Pibrentasvir 40 mg
Composition:
Glecaprevir 100 mg / Pibrentasvir 40 mg
Treatment:
Chronic Hepatitis C (HCV)
Brand:
Mavixen
Manufacturer:
Everest Pharmaceuticals Ltd.
Mavixen (Glecaprevir 100 mg/Pibrentasvir 40 mg) is a fixed-dose combination medicine manufactured by Everest Pharmaceuticals Ltd. It contains two direct-acting antiviral agents, Glecaprevir and Pibrentasvir, which work together to inhibit different proteins essential for hepatitis C virus (HCV) replication. Mavixen is used for the treatment of chronic hepatitis C infection across HCV genotypes 1–6, according to the approved indication and patient-specific medical assessment. Everest officially lists Mavixen under its Hepatitis product portfolio
